Клинико-микробиологическое обоснование использования растительного препарата у детей с ринофарингитом

Введение. Работа включает результаты клинико-микробиологических исследований, определяющих целесообразность использования растительного препарата EPS® 7630 для лечения ринофарингита (РФ) у детей. Во введении представлен краткий обзор литературных данных о роли микробного фактора и важном вкладе дисбиотических нарушений микрофлоры верхних дыхательных путей в развитие РФ. Обозначена роль персистентных свойств условно-патогенных микроорганизмов (УПМ): способность к биопленкообразованию (БПО) и инактивация лизоцима (антилизоцимная активность – АЛА) в качестве дисбиотических маркеров РФ, которые создают условия для рецидивов и хронизации заболевания, снижают эффективность антимикробной терапии.
Цель работы – доказать клинико-микробиологическое обоснование эффективности использования EPS® 7630 в лечении РФ у детей.
Материалы и методы. В исследовании участвовали 79 детей в возрасте от 3 до 15 лет: 1-я группа – 43 ребенка, которым проводилось лечение, включающее, наряду с традиционным лечением, препарат EPS® 7630, 2-я группа (сравнения) – 36 детей, не получавших тестируемый препарат. Микробиологическое исследование проводилось путем взятия мазков из зева и носа до и после лечения; БПО и АЛА определяли по методикам О.В. Бухарина и др. (1999).
Результаты. Проведенные клинические исследования установили сокращение сроков купирования основных симптомов РФ (кашель, ринит, боли в горле, лихорадка) у детей, получавших лечение EPS® 7630 относительно группы сравнения. Микробиологические исследования микроорганизмов, выделенных из носоглотки детей с РФ, выявили способность EPS® 7630 подавлять факторы персистенции бактерий (БПО и АЛА) на 60% и более от исходного уровня.
Выводы. Полученные данные раскрывают один из механизмов антимикробного действия EPS® 7630, заключающийся в подавлении персистентного потенциала УПМ и регулирующем влиянии препарата на микробиоценоз верхних дыхательных путей. Доказана клиническая и микробиологическая эффективность использования EPS® 7630 при лечении РФ у детей.

1. Самсыгина Г.А. Острый ринофарингит у детей, его лечение и профилактика. Педиатрия. Consilium Medicum. 2013;(3):43–47. Режим доступа: https://omnidoctor.ru/upload/iblock/c5e/c5e2a5a6d91e33089541b7b8f1d181c4.pdf.

2. Гострый В.В., Симонова А.В., Михайлова Н.А., Снимщикова И.А., Осипов Г.А., Агафонов Б.В. и др. Хронический фарингит: этиология, патогенез, лечение. Новые подходы к оценке этиопатогенеза. Архивъ внутренней медицины. 2019;9(1):32–43. https://doi.org/10.20514/2226-6704-2019-9-1-32-43.

3. Белов В.А., Белова О.И. Рациональная антибактериальная терапия острого риносинусита у детей. Медицинский совет. 2015;(1):28–31. https://doi.org/10.21518/2079-701X-2015-1-28-31.

4. Giavina-Bianchi P., Aun M.V., Takejima P., Kalil J., Agondi R.C. United airway disease: current perspectives. J Asthma Allergy. 2016;9:93–100. https://doi.org/10.2147/JAA.S81541.

5. Астафьева Н.Г., Кобзев Д.Ю., Гамова И.В. Перфилова И.А., Удовиченко Е.Н., Скучаева Л.В., Михайлова И.Э. Роль микробиома дыхательных путей в респираторном здоровье. Лечащий врач. 2019;(4):12–15. Режим доступа: https://www.lvrach.ru/2019/04/15437250.

6. Медведева Е.А., Мескина Е.Р. Метаболическая активность микрофлоры ротоглотки у детей с бронхитом и внебольничной пневмонией. Альманах клинической медицины. 2015;(42):72–78. Режим доступа: https://www.almclinmed.ru/jour/article/view/38.

7. Stearns J.C., Davidson C.J., McKeon S., Whelan F.J., Fontes M.E., Schryvers A.B. et al. Culture and molecular-based profiles show shifts in bacterial communities of the upper respiratory tract that occur with age. ISME J. 2015;9(5):1246–1259. https://doi.org/10.1038/ismej.2014.250.

8. Sakwinska O., Bastic Schmid V., Berger B., Bruttin A., Keitel K., Lepage M. et al. Nasopharyngeal microbiota in healthy children and pneumonia patients. J Clin Microbiol. 2014;52(5):1590–1594. https://doi.org/10.1128/JCM.03280-13.

9. Chalermwatanachai T., Velásquez L.C., Bachert C. The microbiome of the upper airways: focus on chronic rhinosinusitis. World Allergy Organ J. 2015;8(1):3. https://doi.org/10.1186/s40413-014-0048-6.

10. Караулов А.В. Дисфункции иммунитета при респираторных заболеваниях: нужны ли иммуномодуляторы у часто болеющих детей? Вопросы современной педиатрии. 2015;14(2):260–264. https://doi.org/10.15690/vsp.v14i2.1295.

11. Бухарин О.В., Перунова Н.Б. Микросимбиоценоз. Екатеринбург: УрО РАН; 2014. 260 с.

12. Jamal M., Ahmad W., Andleeb S., Jalil F., Imran M., Nawaz M.A. et al. Bacterial biofilm and associated infections. J Chin Med Assoc. 2018;81(1):7–11. https://doi.org/10.1016/j.jcma.2017.07.012.

13. Gloag E.S., Fabbri S., Wozniak D.J., Stoodley P. Biofilm mechanics: Implications in infection and survival. Biofilm. 2019;2:100017. https://doi.org/10.1016/j.bioflm.2019.100017.

14. Lebeaux D., Ghigo J.M., Beloin C. Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics. Microbiol Mol Biol Rev. 2014;78(3):510–543. https://doi.org/10.1128/MMBR.00013-14.

15. Hanke M.L., Kielian T. Deciphering mechanisms of staphylococcal biofilm evasion of host immunity. Front Cell Infect Microbiol. 2012;2:62. https://doi.org/10.3389/fcimb.2012.00062.

16. Kernien J.F., Snarr B.D., Sheppard D.C., Nett J.E. The Interface between Fungal Biofilms and Innate Immunity. Front Immunol. 2018;8:1968. https://doi.org/10.3389/fimmu.2017.01968.

17. Морозова С.В., Топоркова Л.А. Практическая эффективность фитотерапии инфекционно-воспалительных заболеваний верхних отделов дыхательных путей. Медицинский совет. 2017;(8):80–82. https://doi.org/10.21518/2079-701X-2017-8-80-82.

18. Moyo M., Van Staden J. Medicinal properties and conservation of Pelargonium sidoides DC. J Ethnopharmacol. 2014;152(2):243–255. https://doi.org/10.1016/j.jep.2014.01.009.

19. Careddu D., Pettenazzo A. Pelargonium sidoides extract EPs 7630: a review of its clinical efficacy and safety for treating acute respiratory tract infections in children. Int J Gen Med. 2018;11:91–98. https://doi.org/10.2147/IJGM.S154198.

20. Schapowal A., Dobos G., Cramer H., Ong K.C., Adler M., Zimmermann A. et al. Treatment of signs and symptoms of the common cold using Eps 7630 – results of a meta-analysis. Heliyon. 2019;5(11):e02904. https://doi.org/10.1016/j.heliyon.2019.e02904.

21. Jekabsone A., Sile I., Cochis A., Makrecka-Kuka M., Laucaityte G., Makarova E. et al. Investigation of Antibacterial and Antiinflammatory Activities of Proanthocyanidins from Pelargonium sidoides DC Root Extract. Nutrients. 2019;11(11):2829. https://doi.org/10.3390/nu11112829.

22. Savickiene N., Jekabsone A., Raudone L., Abdelgeliel A.S., Cochis A., Rimondini L. et al. Efficacy of Proanthocyanidins from Pelargonium sidoides Root Extract in Reducing P. gingivalis Viability While Preserving Oral Commensal S. salivarius. Materials (Basel). 2018;11(9):1499. https://doi.org/10.3390/ma11091499.

23. Kardan-Yamchi J., Mahboubi M., Kazemian H., Hamzelou G., Feizabadi M.M. The Chemical Composition and Anti-mycobacterial Activities of Trachyspermum copticum and Pelargonium graveolens Essential Oils. Recent Pat Antiinfect Drug Discov. 2020;15(1):68–74. https://doi.org/10.2174/1574891X14666191028113321.

24. Terlizzi M., Colarusso C., Di Maio U., Pinto A., Sorrentino R. The combination of N-Acetyl-L-Cysteine, Pelargonium sidoides and Justicia adhatoda (NAXX) exerts bacteriostatic activity against S. aureus and E. coli. Nat Prod Res. 2021;35(23):5360–5363. https://doi.org/10.1080/14786419.2020.1761359.

25. Huang S.Y., Yao N., He J.K., Pan M., Hou Z..F, Fan Y.M. et al. In vitro Antiparasitic Activity of Pelargonium X. asperum Essential Oil Against Toxoplasma gondii. Front Cell Dev Biol. 2021;9:616340. https://doi.org/10.3389/fcell.2021.616340.

26. Beil W., Kilian P. EPs 7630, an extract from Pelargonium sidoides roots inhibits adherence of Helicobacter pylori to gastric epithelial cells. Phytomedicine. 2007;14(6 Suppl.):5–8. https://doi.org/10.1016/j.phymed.2006.11.024.

27. Papies J., Emanuel J., Heinemann N., Kulić Ž., Schroeder S., Tenner B. et al. Antiviral and Immunomodulatory Effects of Pelargonium sidoides DC. Root Extract EPs® 7630 in SARS-CoV-2-Infected Human Lung Cells. Front Pharmacol. 2021;12:757666. https://doi.org/10.3389/fphar.2021.757666.

28. Cumaoğlu A., Karatoprak G.Ş., Yerer M.B., Koşar M. Anti-inflammatory Effects of Pelargonium endlicherianum Fenzl. Extracts in Lipopolysaccharide-stimulated Macrophages. Turk J Pharm Sci. 2018;15(1):107–115. https://doi.org/10.4274/tjps.86580.

29. Kolodziej H. Fascinating metabolic pools of Pelargonium sidoides and Pelargonium reniforme, traditional and phytomedicinal sources of the herbal medicine Umckaloabo. Phytomedicine. 2007;14(6 Suppl.):9–17. https://doi.org/10.1016/j.phymed.2006.11.021.

30. Schoetz K., Erdelmeier C., Germer S., Hauer H. A detailed view on the constituents of EPs 7630. Planta Med. 2008;74(6):667–674. https://doi.org/10.1055/s-2008-1074515.

31. Wittschier N., Faller G., Hensel A. An extract of Pelargonium sidoides (EPs 7630) inhibits in situ adhesion of Helicobacter pylori to human stomach. Phytomedicine. 2007;14(4):285–288. https://doi.org/10.1016/j.phymed.2006.12.008.

32. Theisen L.L., Muller CP. EPs® 7630 (Umckaloabo®), an extract from Pelargonium sidoides roots, exerts anti-influenza virus activity in vitro and in vivo. Antiviral Res. 2012;94(2):147–156. https://doi.org/10.1016/j.antiviral.2012.03.006.

33. Helfer M., Koppensteiner H., Schneider M., Rebensburg S., Forcisi S., Müller C. et al. The root extract of the medicinal plant Pelargonium sidoides is a potent HIV-1 attachment inhibitor. PLoS ONE. 2014;9(1):e87487. https://doi.org/10.1371/journal.pone.0087487.

34. Conrad A., Frank U. Extract of Pelargonium sidoides (EPs 7630) displays anti-infective properties by enhanced phagocytosis and differential modulation of host-bacteria interactions. Planta Med. 2008;74(6):682–685. https://doi.org/10.1055/s-2008-1034287.

35. Neugebauer P., Mickenhagen A., Siefer O., Walger M. A new approach to pharmacological effects on ciliary beat frequency in cell cultures – exemplary measurements under Pelargonium sidoides extract (EPs 7630). Phytomedicine. 2005;12(1–2):46–51. https://doi.org/10.1016/j.phymed.2003.11.005.

36. Samie S., Trollope K.M., Joubert L.M., Makunga N.P., Volschenk H. The antifungal and Cryptococcus neoformans virulence attenuating activity of Pelargonium sidoides extracts. J Ethnopharmacol. 2019;235:122–132. https://doi.org/10.1016/j.jep.2019.02.008.

37. Thäle C., Kiderlen A.F., Kolodziej H. Anti-infective activities of Pelargonium sidoides (EPS® 7630): effects of induced NO production on Leishmania major in infected macrophages and antiviral effects as assessed in a fibroblast-virus protection assay. Planta Med. 2011;77(7):718–725. https://doi.org/10.1055/s-0030-1250567.

38. Trun W., Kiderlen A.F., Kolodziej H. Nitric oxide synthase and cytokines gene expression analyses in Leishmania-infected RAW 264.7 cells treated with an extract of Pelargonium sidoides (Eps 7630). Phytomedicine. 2006;13(8):570–575. https://doi.org/10.1016/j.phymed.2005.07.004.

39. Pandey K.B., Rizvi S.I. Plant polyphenols as dietary antioxidants in human health and disease. Oxid Med Cell Longev. 2009;2(5):270–278. https://doi.org/10.4161/oxim.2.5.9498.

40. Yadav M., Jain S., Bhardwaj A., Nagpal R., Puniya M., Tomar R. et al. Biological and medicinal properties of grapes and their bioactive constituents: an update. J Med Food. 2009;12(3):473–484. https://doi.org/10.1089/jmf.2008.0096.

41. Palaska I., Papathanasiou E., Theoharides T.C. Use of polyphenols in periodontal inflammation. Eur J Pharmacol. 2013;720(1–3):77–83. https://doi.org/10.1016/j.ejphar.2013.10.047.

42. Santos-Buelga C., Scalbert A. Proanthocyanidins and tannin-like compounds – nature, occurrence, dietary intake and effects on nutrition and health. J Sci Food Agric. 2000;80:1094–1117. https://doi.org/10.1002/(SICI)1097-0010(20000515)80:7<1094::AID-JSFA569>3.0.CO;2-1.

43. Aron P.M., Kennedy J.A. Flavan-3-ols: nature, occurrence and biological activity. Mol Nutr Food Res. 2008;52(1):79–104. https://doi.org/10.1002/mnfr.200700137.

44. Balalaie A., Rezvani M.B., Mohammadi Basir M. Dual function of proanthocyanidins as both MMP inhibitor and crosslinker in dentin biomodification: A literature review. Dent Mater J. 2018;37(2):173–182. https://doi.org/10.4012/dmj.2017-062.

45. Raudone L., Vilkickyte G., Pitkauskaite L., Raudonis R., Vainoriene R., Motiekaityte V. Antioxidant Activities of Vaccinium vitis-idaea L. Leaves within Cultivars and Their Phenolic Compounds. Molecules. 2019;24(5):844. https://doi.org/10.3390/molecules24050844.

46. Shahzad M., Millhouse E., Culshaw S., Edwards C.A., Ramage G., Combet E. Selected dietary (poly)phenols inhibit periodontal pathogen growth and biofilm formation. Food Funct. 2015;6(3):719–729. https://doi.org/10.1039/c4fo01087f.

47. Ulrey R.K., Barksdale S.M., Zhou W., van Hoek M.L. Cranberry proanthocyanidins have anti-biofilm properties against Pseudomonas aeruginosa. BMC Complement Altern Med. 2014;14:499. https://doi.org/10.1186/1472-6882-14-499.

48. Maisuria V.B., Los Santos Y.L., Tufenkji N., Déziel E. Cranberry-derived proanthocyanidins impair virulence and inhibit quorum sensing of Pseudomonas aeruginosa. Sci Rep. 2016;6:30169. https://doi.org/10.1038/srep30169.

49. Krachler A.M., Orth K. Targeting the bacteria-host interface: strategies in anti-adhesion therapy. Virulence. 2013;4(4):284–294. https://doi.org/10.4161/viru.24606.

50. Terlizzi M., Colarusso C., Di Maio U., Bagnulo A., Pinto A., Sorrentino R. Antioxidant and antimicrobial properties of Pelargonium sidoides DC and lactoferrin combination. Biosci Rep. 2020;40(11):BSR20203284. https://doi.org/10.1042/BSR20203284.

51. Hensel A., Bauer R., Heinrich M., Spiegler V., Kayser O., Hempel G., Kraft K. Challenges at the Time of COVID-19: Opportunities and Innovations in Antivirals from Nature. Planta Med. 2020;86(10):659–664. https://doi.org/10.1055/a-1177-4396.

52. Derksen A., Hensel A., Hafezi W., Herrmann F., Schmidt T.J., Ehrhardt C. et al. 3-O-galloylated procyanidins from Rumex acetosa L. inhibit the attachment of influenza A virus. PLoS ONE. 2014;9(10):e110089. https://doi.org/10.1371/journal.pone.0110089.

53. Quosdorf S., Schuetz A., Kolodziej H. Different Inhibitory Potencies of Oseltamivir Carboxylate, Zanamivir, and Several Tannins on Bacterial and Viral Neuraminidases as Assessed in a Cell-Free Fluorescence-Based Enzyme Inhibition Assay. Molecules. 2017;22(11):1989. https://doi.org/10.3390/molecules22111989.

54. Tsukuda S., Watashi K., Hojima T., Isogawa M., Iwamoto M., Omagari K. et al. A new class of hepatitis B and D virus entry inhibitors, proanthocyanidin and its analogs, that directly act on the viral large surface proteins. Hepatology. 2017;65(4):1104–1116. https://doi.org/10.1002/hep.28952.

55. Dai J., Wang G., Li W., Zhang L., Yang J., Zhao X. et al. High-throughput screening for anti-influenza A virus drugs and study of the mechanism of procyanidin on influenza A virus-induced autophagy. J Biomol Screen. 2012;17(5):605–617. https://doi.org/10.1177/1087057111435236.

56. Lee J.W., Kim Y.I., Im C.N., Kim S.W., Kim S.J., Min S. et al. Grape Seed Proanthocyanidin Inhibits Mucin Synthesis and Viral Replication by Suppression of AP-1 and NF-κB via p38 MAPKs/JNK Signaling Pathways in Respiratory Syncytial Virus-Infected A549 Cells. J Agric Food Chem. 2017;65(22):4472–4483. https://doi.org/10.1021/acs.jafc.7b00923.

57. Liu D.X., Liang J.Q., Fung T.S. Human Coronavirus-229E, -OC43, -NL63, and -HKU1 (Coronaviridae). In: Bamford D.H., Zuckerman M. (eds.). Encyclopedia of Virology. 4th ed. Vol. 2. Academic Press; 2021, pp. 428–440. https://doi.org/10.1016/B978-0-12-809633-8.21501-X.

58. Schildgen O. The Human Coronaviruses. In: Tang Y.W., Stratton C. (eds.). Advanced Techniques in Diagnostic Microbiology. Springer, Cham.; 2018, pp. 269–280. https://doi.org/10.1007/978-3-319-95111-9_11.

59. Pillaiyar T., Meenakshisundaram S., Manickam M. Recent discovery and development of inhibitors targeting coronaviruses. Drug Discov Today. 2020;25(4):668–688. https://doi.org/10.1016/j.drudis.2020.01.015.

60. Rothan H.A., Byrareddy S.N. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433. https://doi.org/10.1016/j.jaut.2020.102433.

61. Michaelis M., Doerr H.W., Cinatl J. Jr. Investigation of the influence of EPs® 7630, a herbal drug preparation from Pelargonium sidoides, on replication of a broad panel of respiratory viruses. Phytomedicine. 2011;18(5):384–386. https://doi.org/10.1016/j.phymed.2010.09.008.

62. Roth M., Fang L., Stolz D., Tamm M. Pelargonium sidoides radix extract Eps 7630 reduces rhinovirus infection through modulation of viral binding proteins on human bronchial epithelial cells. PLoS ONE. 2019;14(2):e0210702. https://doi.org/10.1371/journal.pone.0210702.

63. Arulselvan P., Fard M.T., Tan W.S., Gothai S., Fakurazi S., Norhaizan M.E., Kumar S.S. Role of Antioxidants and Natural Products in Inflammation. Oxid Med Cell Longev. 2016;5276130. https://doi.org/10.1155/2016/5276130.

64. Yamakoshi J., Saito M., Kataoka S., Kikuchi M. Safety evaluation of proanthocyanidin-rich extract from grape seeds. Food Chem Toxicol. 2002;40(5):599–607. https://doi.org/10.1016/s0278-6915(02)00006-6.

65. Witte K., Koch E., Volk H.D., Wolk K., Sabat R. The herbal extract EPs® 7630 increases the antimicrobial airway defense through monocytedependent induction of IL-22 in T cells. J Mol Med (Berl). 2020;98(10):1493–1503. https://doi.org/10.1007/s00109-020-01970-3.

66. Antonelli M., Donelli D., Maggini V., Firenzuoli F. Phytotherapic compounds against coronaviruses: Possible streams for future research. Phytother Res. 2020;34(7):1469–1470. https://doi.org/10.1002/ptr.6712.

67. Brendler T., Al-Harrasi A., Bauer R., Gafner S., Hardy M.L., Heinrich M. et al. Botanical drugs and supplements affecting the immune response in the time of COVID-19: Implications for research and clinical practice. Phytother Res. 2021;35(6):3013–3031. https://doi.org/10.1002/ptr.7008.

68. Mani J.S., Johnson J.B., Steel J.C., Broszczak D.A., Neilsen P.M., Walsh K.B., Naiker M. Natural product-derived phytochemicals as potential agents against coronaviruses: A review. Virus Res. 2020;284:197989. https://doi.org/10.1016/j.virusres.2020.197989.

69. Silveira D., Prieto-Garcia J.M., Boylan F., Estrada O., Fonseca-Bazzo Y.M., Jamal C.M. et al. COVID-19: Is There Evidence for the Use of Herbal Medicines as Adjuvant Symptomatic Therapy? Front Pharmacol. 2020;11:581840. https://doi.org/10.3389/fphar.2020.581840.

70. Seifert G., Brandes-Schramm J., Zimmermann A., Lehmacher W., Kamin W. Faster recovery and reduced paracetamol use – a meta-analysis of Eps 7630 in children with acute respiratory tract infections. BMC Pediatr. 2019;19(1):119. https://doi.org/10.1186/s12887-019-1473-z.

71. Wopker P.M., Schwermer M., Sommer S., Längler A., Fetz K., Ostermann T., Zuzak T.J. Complementary and alternative medicine in the treatment of acute bronchitis in children: A systematic review. Complement Ther Med. 2020;49:102217. https://doi.org/10.1016/j.ctim.2019.102217.

72. Seifert G., Funk P., Reineke T., Lehmacher W. Influence of EPs 7630 on Antipyretic Comedication and Recovery from Acute Tonsillopharyngitis in Children: a Meta-Analysis of Randomized, Placebo-Controlled, Clinical Trials. J Pediatr Infect Dis. 2021;16(03):122–128. https://doi.org/10.1055/s-0040-1722205.

73. O’Toole G.A., Kolter R. Initiation of biofilm formation in Pseudomonas fluorescens WCS365 proceeds via multiple, convergent signalling pathways: a genetic analysis. Mol Microbiol. 1998;28(3):449–461. https://doi.org/10.1046/j.1365-2958.1998.00797.x.

74. Бухарин О.В. Персистенция патогенных бактерий. М.: Медицина; 1999.365 с.

75. Keck T., Strobl A., Weinhaeusel A., Funk P., Michaelis M. Pelargonium Extract EPs 7630 in the Treatment of Human Corona Virus-Associated Acute Respiratory Tract Infections – A Secondary Subgroup-Analysis of an Open-Label, Uncontrolled Clinical Trial. Front Pharmacol. 2021;12:666546. https://doi.org/10.3389/fphar.2021.666546.